+

PL1730151T5 - Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone - Google Patents

Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Info

Publication number
PL1730151T5
PL1730151T5 PL05730345.5T PL05730345T PL1730151T5 PL 1730151 T5 PL1730151 T5 PL 1730151T5 PL 05730345 T PL05730345 T PL 05730345T PL 1730151 T5 PL1730151 T5 PL 1730151T5
Authority
PL
Poland
Prior art keywords
hydroxycodeinone
ppm
less
oxycodone hydrochloride
preparing oxycodone
Prior art date
Application number
PL05730345.5T
Other languages
Polish (pl)
Other versions
PL1730151T3 (en
Inventor
Robert Chapman
Lonn S. Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1730151(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of PL1730151T3 publication Critical patent/PL1730151T3/en
Publication of PL1730151T5 publication Critical patent/PL1730151T5/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PL05730345.5T 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone PL1730151T5 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10
PCT/US2005/010666 WO2005097801A1 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
EP05730345.5A EP1730151B2 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Publications (2)

Publication Number Publication Date
PL1730151T3 PL1730151T3 (en) 2011-08-31
PL1730151T5 true PL1730151T5 (en) 2023-09-18

Family

ID=35124996

Family Applications (5)

Application Number Title Priority Date Filing Date
PL10011788T PL2316837T3 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone
PL10011787.8T PL2319846T3 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone
PL10011792T PL2305683T3 (en) 2004-03-30 2005-03-30 Pharmaceutical dosage form comprising oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
PL05730345.5T PL1730151T5 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
PL11186168T PL2426132T3 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride compositions having less than 25ppm 14-hydroxycodeinone

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL10011788T PL2316837T3 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone
PL10011787.8T PL2319846T3 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone
PL10011792T PL2305683T3 (en) 2004-03-30 2005-03-30 Pharmaceutical dosage form comprising oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11186168T PL2426132T3 (en) 2004-03-30 2005-03-30 Process for preparing oxycodone hydrochloride compositions having less than 25ppm 14-hydroxycodeinone

Country Status (39)

Country Link
US (35) US7129248B2 (en)
EP (7) EP1730151B2 (en)
JP (8) JP4912294B2 (en)
KR (12) KR20120046309A (en)
CN (5) CN1960994B (en)
AP (1) AP2232A (en)
AR (1) AR049012A1 (en)
AT (2) ATE501150T1 (en)
AU (2) AU2005230826C1 (en)
BR (1) BRPI0508758B8 (en)
CA (3) CA2557845C (en)
CR (2) CR8593A (en)
CY (5) CY1111487T1 (en)
DE (2) DE202005021371U1 (en)
DK (6) DK2316837T3 (en)
EA (1) EA013208B1 (en)
EC (1) ECSP066953A (en)
ES (6) ES2665287T3 (en)
FI (1) FI7843U1 (en)
HK (3) HK1098745A1 (en)
HR (5) HRP20110425T4 (en)
HU (3) HUE029913T2 (en)
IL (8) IL178038A (en)
LT (2) LT2314589T (en)
MA (1) MA28492B1 (en)
ME (4) ME02482B (en)
MX (2) MX363228B (en)
MY (3) MY172063A (en)
NO (1) NO337669B1 (en)
NZ (3) NZ549430A (en)
PE (1) PE20050880A1 (en)
PL (5) PL2316837T3 (en)
PT (5) PT1730151E (en)
RS (5) RS51693B2 (en)
SG (3) SG10201406658VA (en)
SI (5) SI1730151T2 (en)
TW (3) TWI483944B (en)
WO (1) WO2005097801A1 (en)
ZA (1) ZA200607181B (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (en) * 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102004020220A1 (en) * 2004-04-22 2005-11-10 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102005005446A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10361596A1 (en) * 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
BRPI0413361B8 (en) * 2003-08-06 2021-05-25 Gruenenthal Gmbh abuse-safe tablet thermoformed by non-bleaching extrusion
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI483944B (en) 2004-03-30 2015-05-11 Euro Celtique Sa Oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oral dosage form,and pharmaceutically acceptable package having less than 25 ppm 14-hydroxycodeinone
DE102004032049A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102004032103A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
SI1861405T1 (en) * 2005-03-04 2009-10-31 Euro Celtique Sa Method of reducing alpha, beta- unsaturated ketones in opioid compositions
WO2007011819A2 (en) * 2005-07-15 2007-01-25 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
EP1971607A2 (en) * 2005-11-22 2008-09-24 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
JP5695296B2 (en) 2006-03-02 2015-04-01 マリンクロッド エルエルシー Process for the production of morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US8134002B2 (en) * 2006-10-17 2012-03-13 Penick Corporation Process for preparing oxymorphone
CN101652369A (en) * 2006-12-04 2010-02-17 诺拉姆科有限公司 Reduce the method for impurity in the oxycodone base
CN101652370A (en) * 2006-12-04 2010-02-17 诺拉姆科有限公司 The method of the oxycodone that preparation 14-hydroxycodeine ketone level reduces
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
EP2125824B2 (en) * 2007-03-23 2023-11-15 Mallinckrodt LLC Improved preparation of oxymorphone from oripavine
EP2137190B1 (en) * 2007-04-16 2013-06-12 Mallinckrodt LLC Novel opiate reduction utilizing catalytic hydrogen transfer reaction
MX2010008138A (en) 2008-01-25 2010-08-10 Gruenenthal Gmbh Pharmaceutical dosage form.
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
MX2010009990A (en) * 2008-03-11 2010-12-15 Depomed Inc Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic.
LT2273983T (en) 2008-05-09 2016-10-25 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2010032128A1 (en) * 2008-09-18 2010-03-25 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
MX2012000317A (en) * 2009-07-22 2012-02-08 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form.
PE20120631A1 (en) 2009-07-22 2012-06-06 Gruenenthal Chemie HANDLING RESISTANT DOSAGE FORM FOR OPIOIDS SENSITIVE TO OXIDATION
WO2011026125A2 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
ES2569925T3 (en) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Methods and compositions of deterrence of abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2606227T3 (en) * 2010-02-03 2017-03-23 Grünenthal GmbH Preparation of a pharmaceutical powder composition by an extruder
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
NZ603497A (en) 2010-05-10 2015-02-27 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
CN103002881B (en) 2010-05-10 2015-09-02 欧洲凯尔特公司 The granule of carrying active agent and the combination of additional active agent
EP2580201B1 (en) 2010-06-11 2017-08-02 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
WO2011154826A1 (en) 2010-06-11 2011-12-15 Rhodes Technologies Process for n-dealkylation of tertiary amines
US8703950B2 (en) 2010-07-02 2014-04-22 Johnson Matthey Public Limited Co. Low ABUK oxycodone, its salts and methods of making same
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
CN103179954A (en) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 Shatter-resistant dosage forms containing anionic polymers
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
DK2736495T3 (en) 2011-07-29 2017-11-13 Gruenenthal Gmbh ABUSE RESPONSIBLE TABLE THAT PROVIDES IMMEDIATE RELEASE OF MEDICINE
PL2736497T3 (en) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
ES2842453T3 (en) 2011-09-05 2021-07-14 Siegfried Ltd Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
MX355478B (en) 2011-09-16 2018-04-19 Purdue Pharma Lp Tamper resistant pharmaceutical formulations.
EP3078370B1 (en) 2011-09-16 2018-11-07 Purdue Pharma L.P. Tamper resistant immediate release formulations
JP6144274B2 (en) 2011-12-09 2017-06-07 パーデュー、ファーマ、リミテッド、パートナーシップ Pharmaceutical dosage forms comprising poly (epsilon-caprolactone) and polyethylene oxide
MX356421B (en) 2012-02-28 2018-05-29 Gruenenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer.
EP2819653B1 (en) 2012-03-02 2017-01-11 Rhodes Pharmaceuticals L.P. Tamper resistant immediate release formulations
TWI522101B (en) 2012-04-17 2016-02-21 普渡製藥有限合夥事業 Systems and methods for treating an opioid-induced adverse pharmacodynamic response
ES2692944T3 (en) 2012-04-18 2018-12-05 Grünenthal GmbH Pharmaceutical dosage form resistant to handling and resistant to rapid discharge of the dose
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
PL2872121T3 (en) 2012-07-12 2019-02-28 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
US10316042B2 (en) 2012-07-16 2019-06-11 Rhodes Technologies Process for improved opioid synthesis
CA2879268C (en) * 2012-07-16 2018-05-08 Rhodes Technologies Process for improved opioid synthesis
HUE042762T2 (en) * 2012-08-03 2019-07-29 Johnson Matthey Plc A method for preparing oxycodone
ES2691982T3 (en) 2012-11-30 2018-11-29 Acura Pharmaceuticals, Inc. Self-regulated release of an active pharmaceutical ingredient
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014130714A1 (en) * 2013-02-20 2014-08-28 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6445537B2 (en) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper-resistant dosage forms containing one or more particles
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
CA2917136C (en) 2013-07-12 2022-05-31 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
WO2015015146A1 (en) 2013-08-02 2015-02-05 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
BR112016008459B1 (en) 2013-11-07 2023-02-07 SpecGx LLC PRODUCTION OF 6-HYDROXY MORPHINANS WITHOUT ISOLATING INTERMEDIATES
BR112016009749A8 (en) 2013-11-13 2018-01-30 Euro Celtique Sa hydromorphone and naloxone for treatment of pain and opioid intestinal dysfunction syndrome
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9938285B2 (en) 2014-01-15 2018-04-10 Rhodes Technologies Process for improved oxymorphone synthesis
EP3094634A1 (en) 2014-01-15 2016-11-23 Rhodes Technologies Process for improved oxycodone synthesis
WO2015120201A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
AU2015237723B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
WO2016005923A1 (en) 2014-07-09 2016-01-14 Rhodes Technologies Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) * 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (en) * 2014-12-15 2017-11-24 北大方正集团有限公司 The preparation method of the methylnaltrexone bromides of Delta 7
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
BR112017021475A2 (en) 2015-04-24 2018-07-10 Gruenenthal Gmbh tamper-resistant dosage form with immediate release and resistance to solvent extraction
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018055199A1 (en) 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
AU2018287728B2 (en) 2017-06-20 2021-10-28 Macfarlan Smith Limited Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone
BR112019027889A2 (en) 2017-06-30 2020-07-07 Purdue Pharma L.P. treatment method and dosage forms
CN110330500B (en) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 Stereoselective synthesis method of 6 beta-hydroxy-7, 8-dihydro-morphine derivative
CN113009060B (en) * 2021-02-24 2022-10-21 西南药业股份有限公司 Method for determining content of oxycodone hydrochloride by high performance liquid chromatography

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US420098A (en) * 1890-01-28 Mowing-machine
US1468805A (en) 1923-09-25 Htabtin ereund
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US1485673A (en) * 1924-03-04 Ministrator
DE286431C (en)
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
DE296916C (en) *
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (en) 1944-01-26 1944-11-30 А.И. Лютенберг The method of obtaining dihydrooxycodeodeinone hydrochloride
ES212554A1 (en) 1953-12-01 1954-08-16 Casanovas Albajes Cesar A procedure for the obtaining of an organic glass (Machine-translation by Google Translate, not legally binding)
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (en) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (en) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
KR930001499B1 (en) * 1987-07-07 1993-03-02 오끼뎅끼 고오교오 가부시끼가이샤 Manufacturing method of semiconductor device
DE3812567A1 (en) 1988-04-15 1989-10-26 Basf Ag METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (en) * 1996-01-26 2003-08-04 株式会社デンソー Integrated semiconductor strain sensor and method of manufacturing the same
AU3508097A (en) 1996-06-26 1998-01-14 Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (en) * 1996-12-23 1999-06-16 Univ Santiago Compostela PROCEDURE FOR OBTAINING 14-HYDROXIMOFINONES BY PHOTOOXIDATION OF MORPHINE ALKALOIDS WITH ALCOXIDIENIC SYSTEM IN RING C.
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
ATE251017T1 (en) * 1998-10-14 2003-10-15 Gyros Ab MOLD AND METHOD FOR PRODUCING THE SAME
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
GEP20053614B (en) * 2000-02-08 2005-09-26 Euro Celtique Sa Compositions for Oral Administration Containing Opioid Agonist
US20030194748A1 (en) 2000-05-29 2003-10-16 Tohru Nagasaki Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (en) 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
KR20040014544A (en) * 2001-06-05 2004-02-14 컨트롤 딜리버리 시스템즈 인코포레이티드 Sustained-release analgesic compounds
EP1392250A2 (en) 2001-06-08 2004-03-03 Endo Pharmaceuticals Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
DE60230632D1 (en) 2001-07-18 2009-02-12 Euro Celtique Sa PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE
AU2003235678A1 (en) * 2002-01-15 2003-07-30 Aerogen, Inc. Systems and methods for clearing aerosols from the effective anatomic dead space
US7790215B2 (en) * 2002-03-26 2010-09-07 Purdue Pharma Lp Sustained-release gel coated compositions
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
EP1509050A4 (en) * 2002-05-27 2009-03-18 Ntt Docomo Inc MOBILE COMMUNICATION SYSTEM, TRANSMISSION STATION, RECEPTION STATION, RELAY STATION, COMMUNICATION PATH DECISION METHOD, AND COMMUNICATION PATH DECISION SOFTWARE
RU2004134728A (en) 2002-05-31 2005-06-10 Алза Корпорейшн (Us) DOSED FORMS AND COMPOSITIONS FOR THE OSMOTIC DELIVERY OF VARIOUS DOSAGE OXYCODONE
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
US7534888B2 (en) * 2002-08-15 2009-05-19 Noramco, Inc. Oxycodone polymorphs
US7192966B2 (en) 2002-11-15 2007-03-20 Branded Products For The Future Pharmaceutical composition
WO2004050025A2 (en) * 2002-11-29 2004-06-17 Forest Laboratories, Inc. Combination of ibuprofen and oxycodone for acute pain relief
FR2850576B1 (en) * 2003-02-05 2007-03-23 Ethypharm Sa COMPOSITION COMPRISING A MIXTURE OF ACTIVE INGREDIENTS AND PROCESS FOR PREPARING THE SAME
US7230005B2 (en) 2003-03-13 2007-06-12 Controlled Chemicals, Inc. Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
TWI483944B (en) 2004-03-30 2015-05-11 Euro Celtique Sa Oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oral dosage form,and pharmaceutically acceptable package having less than 25 ppm 14-hydroxycodeinone
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
JP5329083B2 (en) 2004-06-25 2013-10-30 テッセラ，インコーポレイテッド Parts with posts and pads
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
SI1861405T1 (en) 2005-03-04 2009-10-31 Euro Celtique Sa Method of reducing alpha, beta- unsaturated ketones in opioid compositions
DE602006019246D1 (en) 2005-06-16 2011-02-10 Mallinckrodt Inc SYNTHETIC ROUTE TO 14-HYDROXYLOPIATES OVER 1-HALOGENHEBINE OR ANALOG
EP1971607A2 (en) 2005-11-22 2008-09-24 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
JP5695296B2 (en) 2006-03-02 2015-04-01 マリンクロッド エルエルシー Process for the production of morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
CN101652369A (en) 2006-12-04 2010-02-17 诺拉姆科有限公司 Reduce the method for impurity in the oxycodone base
CN101652370A (en) * 2006-12-04 2010-02-17 诺拉姆科有限公司 The method of the oxycodone that preparation 14-hydroxycodeine ketone level reduces
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
US8703950B2 (en) * 2010-07-02 2014-04-22 Johnson Matthey Public Limited Co. Low ABUK oxycodone, its salts and methods of making same
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
PL2316837T3 (en) 2018-07-31
US20160251363A1 (en) 2016-09-01
MX363228B (en) 2019-03-15
MX2020008878A (en) 2020-11-09
US20160250205A1 (en) 2016-09-01
IL213891A0 (en) 2011-07-31
JP2012072162A (en) 2012-04-12
HK1155728A1 (en) 2012-05-25
IL213889A0 (en) 2011-07-31
NZ601326A (en) 2013-10-25
DK1730151T3 (en) 2011-06-20
CY1117841T1 (en) 2017-05-17
HRP20110425T1 (en) 2011-07-31
ES2665287T3 (en) 2018-04-25
NO20064935L (en) 2006-12-18
PL2305683T3 (en) 2015-07-31
US7683072B2 (en) 2010-03-23
LT2316837T (en) 2018-04-10
EP2426132B1 (en) 2016-01-13
ATE501150T1 (en) 2011-03-15
US10689389B2 (en) 2020-06-23
KR20110110377A (en) 2011-10-06
ME03068B (en) 2019-01-20
US20100152449A1 (en) 2010-06-17
MY172063A (en) 2019-11-13
CN1960994A (en) 2007-05-09
US20210094963A1 (en) 2021-04-01
CA2557845A1 (en) 2005-10-20
CA2557845C (en) 2013-10-01
PL2426132T3 (en) 2016-06-30
US10407434B2 (en) 2019-09-10
DE202005021371U1 (en) 2007-10-25
US9777011B2 (en) 2017-10-03
RS54598B1 (en) 2016-08-31
EP2319846B1 (en) 2016-05-04
MY154985A (en) 2015-08-28
US20070117830A1 (en) 2007-05-24
IL241117A0 (en) 2015-11-30
JP2018184462A (en) 2018-11-22
PT1730151E (en) 2011-06-01
US20070117831A1 (en) 2007-05-24
AU2005230826B2 (en) 2008-11-06
US9522919B2 (en) 2016-12-20
PT2319846T (en) 2016-08-12
US20160264588A1 (en) 2016-09-15
TW200540177A (en) 2005-12-16
JP2015187134A (en) 2015-10-29
IL213888A0 (en) 2011-07-31
SI1730151T2 (en) 2021-03-31
PL2319846T3 (en) 2016-12-30
JP2007531756A (en) 2007-11-08
IL214050A (en) 2013-09-30
JP6503392B2 (en) 2019-04-17
IL213889A (en) 2012-06-28
US20230159548A1 (en) 2023-05-25
EP1730151A1 (en) 2006-12-13
US9073933B2 (en) 2015-07-07
RS54941B1 (en) 2016-11-30
EP2314589A1 (en) 2011-04-27
EP2316837B1 (en) 2018-01-10
ES2362282T5 (en) 2021-06-24
US20160251364A1 (en) 2016-09-01
SI2426132T1 (en) 2016-04-29
AP2232A (en) 2011-05-04
CN102127086B (en) 2013-11-27
AU2005230826A1 (en) 2005-10-20
SG10201406658VA (en) 2014-12-30
SI2316837T1 (en) 2018-05-31
US20150258086A1 (en) 2015-09-17
US20160185788A1 (en) 2016-06-30
JP5118223B2 (en) 2013-01-16
KR20140021716A (en) 2014-02-20
US20210198268A1 (en) 2021-07-01
HK1155729A1 (en) 2012-05-25
ECSP066953A (en) 2006-12-20
US20160185790A1 (en) 2016-06-30
PT2426132E (en) 2016-03-31
BRPI0508758A (en) 2007-08-28
CY1116327T1 (en) 2017-02-08
KR20070022033A (en) 2007-02-23
US20180022754A1 (en) 2018-01-25
PT2316837T (en) 2018-04-02
US10696684B2 (en) 2020-06-30
HUE029913T2 (en) 2017-04-28
EA013208B1 (en) 2010-04-30
KR20150046393A (en) 2015-04-29
RS51693B (en) 2011-10-31
MY143205A (en) 2011-03-31
US20130005977A1 (en) 2013-01-03
AU2009200335A1 (en) 2009-02-26
ME02411B (en) 2016-09-20
JP2011157370A (en) 2011-08-18
LT2314589T (en) 2023-06-12
US20070179169A1 (en) 2007-08-02
IL178038A (en) 2015-10-29
ES2362282T3 (en) 2011-06-30
HUE028233T2 (en) 2016-12-28
CN102887903A (en) 2013-01-23
CY1120171T1 (en) 2018-12-12
CN101812065A (en) 2010-08-25
IL214050A0 (en) 2011-08-31
US7129248B2 (en) 2006-10-31
IL235298A (en) 2016-11-30
EP2311839A1 (en) 2011-04-20
EP2305683B2 (en) 2024-09-11
US20200062772A1 (en) 2020-02-27
NZ549430A (en) 2010-05-28
JP5543991B2 (en) 2014-07-09
JP2017125052A (en) 2017-07-20
RS51693B2 (en) 2021-02-26
CY1117228T1 (en) 2017-04-05
US20160250204A1 (en) 2016-09-01
HK1098745A1 (en) 2007-07-27
NO337669B1 (en) 2016-05-30
US20160176888A1 (en) 2016-06-23
CN102887903B (en) 2016-01-27
EP1730151A4 (en) 2007-05-23
EP2316837A1 (en) 2011-05-04
US7674799B2 (en) 2010-03-09
CA2774121A1 (en) 2005-10-20
EP2305683A1 (en) 2011-04-06
SI2319846T1 (en) 2016-08-31
HUE036451T2 (en) 2018-07-30
KR20100069719A (en) 2010-06-24
DK200700214U3 (en) 2008-02-08
ZA200607181B (en) 2007-11-28
EP1730151B2 (en) 2020-09-16
JP2014139205A (en) 2014-07-31
AU2009200335B2 (en) 2011-07-28
TW201231469A (en) 2012-08-01
US20150265598A1 (en) 2015-09-24
PE20050880A1 (en) 2005-11-16
SI1730151T1 (en) 2011-06-30
TW201509943A (en) 2015-03-16
SG170736A1 (en) 2011-05-30
BRPI0508758B8 (en) 2021-05-25
KR20140133615A (en) 2014-11-19
DE602005026786D1 (en) 2011-04-21
US7674798B2 (en) 2010-03-09
EP2305683B1 (en) 2015-01-28
IL213890A (en) 2015-10-29
RS57000B1 (en) 2018-05-31
US7674800B2 (en) 2010-03-09
KR101410141B1 (en) 2014-06-25
US20200087316A1 (en) 2020-03-19
ES2938727T3 (en) 2023-04-14
EP2426132A1 (en) 2012-03-07
DK2316837T3 (en) 2018-04-16
US20160251365A1 (en) 2016-09-01
KR20120106784A (en) 2012-09-26
KR20180088505A (en) 2018-08-03
CA2774121C (en) 2016-02-16
EP2314589B1 (en) 2022-12-28
US20160175298A1 (en) 2016-06-23
AT9952U1 (en) 2008-06-15
IL241117B (en) 2020-06-30
KR20120046309A (en) 2012-05-09
HRP20160885T1 (en) 2016-09-23
DK2305683T3 (en) 2015-04-07
DK1730151T4 (en) 2020-10-19
US20060173029A1 (en) 2006-08-03
KR100930730B1 (en) 2009-12-09
CN102838607B (en) 2016-08-03
TWI365880B (en) 2012-06-11
ES2535618T3 (en) 2015-05-13
US10259819B2 (en) 2019-04-16
ME02482B (en) 2017-02-20
CY1111487T1 (en) 2015-08-05
AR049012A1 (en) 2006-06-21
US20160175300A1 (en) 2016-06-23
IL213890A0 (en) 2011-07-31
PT2305683E (en) 2015-05-18
CN1960994B (en) 2012-09-05
JP5378486B2 (en) 2013-12-25
US20050222188A1 (en) 2005-10-06
ES2585576T3 (en) 2016-10-06
ME01299B (en) 2011-10-31
US11384091B2 (en) 2022-07-12
CN102838607A (en) 2012-12-26
KR20200000499A (en) 2020-01-02
EP2305683B8 (en) 2015-03-04
US20230365578A1 (en) 2023-11-16
JP2012188439A (en) 2012-10-04
RS53891B1 (en) 2015-08-31
KR101200700B1 (en) 2012-11-13
KR20130020962A (en) 2013-03-04
US12060361B2 (en) 2024-08-13
AP2006003738A0 (en) 2006-10-31
WO2005097801A1 (en) 2005-10-20
MA28492B1 (en) 2007-03-01
DK2426132T3 (en) 2016-04-04
US20190161492A1 (en) 2019-05-30
EP2319846A1 (en) 2011-05-11
US20150265597A1 (en) 2015-09-24
KR100993911B1 (en) 2010-11-11
EA200601520A1 (en) 2007-02-27
CR8593A (en) 2007-07-19
US20160175299A1 (en) 2016-06-23
CR20110376A (en) 2011-09-19
SI2305683T1 (en) 2015-04-30
PL1730151T3 (en) 2011-08-31
US20090227615A1 (en) 2009-09-10
US20160185789A1 (en) 2016-06-30
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
HRP20180407T1 (en) 2018-04-20
US20070117829A1 (en) 2007-05-24
TWI483944B (en) 2015-05-11
SG170735A1 (en) 2011-05-30
CA2913355A1 (en) 2005-10-20
HRP20110425T4 (en) 2020-11-27
CA2913355C (en) 2021-04-20
AU2005230826C1 (en) 2014-10-16
JP4912294B2 (en) 2012-04-11
BRPI0508758B1 (en) 2018-10-09
DK200700214U1 (en) 2007-11-23
ES2566363T3 (en) 2016-04-12
HRP20150358T1 (en) 2015-05-08
KR20090104145A (en) 2009-10-05
HRP20160223T1 (en) 2016-03-25
IL178038A0 (en) 2006-12-31
FIU20070284U0 (en) 2007-07-04
FI7843U1 (en) 2008-04-28
EP1730151B1 (en) 2011-03-09
CN101812065B (en) 2012-03-28
CN102127086A (en) 2011-07-20
US20160176889A1 (en) 2016-06-23
US20110207762A1 (en) 2011-08-25
US8822687B2 (en) 2014-09-02
DK2319846T3 (en) 2016-08-15

Similar Documents

Publication Publication Date Title
IL235298A (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
GEP20094655B (en) Process for preparing oxycodone hydrochloride having less than 25 pm 14-hydroxycodeinone
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载